EcoDrugPlus

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSHCOG00000006609
Gene Symbol: LOC109509731
3 Cross references
211 Possible Orthologues:

Methionyl Aminopeptidase 2

Ensembl ID : ENSHCOG00000003805
Gene Symbol: METAP2
4 Cross references
220 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSHCOG00000008447
Gene Symbol: MAPK1
3 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSHCOG00000014759
Gene Symbol: LOC109514865
3 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSHCOG00000011085
Gene Symbol: MAPK10
3 Cross references
88 Possible Orthologues:

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSHCOG00000005608
Gene Symbol: LOC109531842
3 Cross references
181 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSHCOG00000004282
Gene Symbol: MAPK14
3 Cross references
206 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a

Ensembl ID : ENSHCOG00000009841
Gene Symbol: LOC109522222
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSHCOG00000009511
Gene Symbol: LOC109513124
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSHCOG00000019799
Gene Symbol: LOC109512691
3 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSHCOG00000016050
Gene Symbol: MAPK9
3 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSHCOG00000014666
Gene Symbol: MAP2K1
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).